follow us in feedly
MicroSmallCap

Join Our Community

Facebook

Twitter

RSS

      • Featured
      • Penny Stocks
        • Penny Stocks to Buy
        • Penny Stocks to Sell
        • Robinhood Penny Stocks
      • Robinhood Stocks
        • Top 100
        • Penny Stocks
      • Market Movers
        • Analyst Coverage
        • Earnings Reports
        • Low Float Stocks
        • PDUFA Stage
        • Short Squeeze Stocks
        • Stock Price Target Changes
        • Stocks to Buy
        • Stocks to Sell
      • Sectors
        • Cannabis
        • Consumer
        • Energy
        • Financial
        • Health
        • Mining
        • Tech
      • NewsHub
      HomeAuthorsAnkit Singhania

      Articles by Ankit Singhania

      Ankit Singhania
      Based in India, Ankit is a financial content writer and stock market analyst. He has worked for almost a decade on several financial projects related to the stock market news, fundamental research and technical analysis for several websites. He obtained his Masters Degree In finance (MS – finance) from ICFAI. Currently, he serves as a financial consultant and technical analyst at Tradersinsights.com.
      MEIP stock
      Drug Manufacturers

      MEIP Stock Gains Momentum on Early-Stage Trial Data

      Oct 4 Ankit Singhania
      When a pharmaceutical company provides a positive update with regards to any of its products, then the stock almost always rises, and that is what has happened with MEIP stock. Positive Development MEI Pharma Inc ... [Read]
      GPRO stock
      Computer Hardware

      GPRO Stock Down 21% After Slashing Guidance Following Production Delays

      Oct 3 Ankit Singhania
      On Thursday, GPRO stock plunged 19% after GoPro Inc. (NASDAQ:GPRO) reduced its revenue and profit estimate for the latter half of 2019 because of production delays of its new Hero8 Black cameras. GoPro to Commence ... [Read]
      NIO stock
      Autos

      NIO Stock Plunges 60% in 2 Weeks: Analysts are Still Skeptical

      Oct 2 Ankit Singhania
      Chinese electric carmaker NIO Inc (NYSE:NIO) is struggling after the company reported a wider-than-expected loss in Q2 as well as several layoffs in late September. NIO stock has lost 60% since September 20. Disappointing Q2 ... [Read]
      GPRO stock
      Computer Hardware

      GPRO Stock Jumps 30% in a Week: Is it a Reversal?

      Oct 1 Ankit Singhania
      GPRO stock has been gaining momentum over the past week, with a gain of about 30% and up 50% over the course of September. The stock gained even though there was no specific news from ... [Read]
      TROV stock
      Biotechnology

      TROV Stock Soars 22% on Positive Mid-Stage Data at ESMO

      Sep 30 Ankit Singhania
      TROV stock is one of the biggest biotech stock gainers this morning after TrovaGene Inc (NASDAQ:TROV) reported positive results from its Phase 1b/2 study of onvansertib. Key Details Companies in the therapeutics space strive for ... [Read]
      PRGS stock
      Application Software

      PRGS Stock Plunges 12% After Lower-Than-Excepted Q3 Sales

      Sep 27 Ankit Singhania
      On Friday, PRGS stock slumped 12% after Progress Software Corp (NASDAQ:PRGS) reported lower-than-expected sales in the third quarter. Moreover, the company lowered its revenue estimate for the current quarter to $116–119 million from $122.1 million. ... [Read]
      PIR stock
      Retail

      PIR Stock Tumbles 16% on Significant Q2 Loss: What Next?

      Sep 26 Ankit Singhania
      PIR stock is one of the leading losers on Thursday after Pier 1 Imports Inc (NYSE:PIR) reported that comparable sales fell 12.6% in Q2 and gross margin tumbled as well. Increased Q2 Loss Over the ... [Read]
      ACHN stock
      Biotechnology

      ACHN Stock Zooms 17% as FDA Grants BTD for Danicopan

      Sep 25 Ankit Singhania
      ACHN stock is leading in the biotech sector after Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that the FDA has granted Breakthrough Therapy Designation (BTD) for danicopan (ACH-4471). Investors Cheer the News When a pharmaceutical company releases ... [Read]
      OVID stock
      Biotechnology

      OVID Stock Soars 40% in 2 Sessions on Preliminary Drug Results

      Sep 24 Ankit Singhania
      OVID stock is one of the biggest penny stock gainers in the biotech sector this week after Ovid Therapeutics Inc (NASDAQ:OVID) reported preliminary results from a Phase 2 open-label extension study. Positive Momentum Ovid Therapeutics ... [Read]
      OSTK stock
      Retail

      OSTK Stock Slumps 15% on Revised Retail Sales for 2019

      Sep 23 Ankit Singhania
      OSTK stock is one of the biggest losers on Monday after Overstock.com Inc (NASDAQ:OSTK) lowered its retail guidance for the full year. Weak Outlook and New CEO When companies make major announcements before the markets ... [Read]

      Posts pagination

      « 1 … 14 15 16 … 27 »

      YOU MAY ALSO LIKE

      • Optimi Health
        Optimi Health Has Completed the Largest Legal Harvest of Natural Psilocybin in Canadian History.
        Sep 15 Chinedu Okoro
      • Cardinal Health Reveals Governance Enhancements And Shareholder Value Creation Programs
        Cardinal Health Reveals Governance Enhancements And Shareholder Value Creation Programs
        Sep 9 Adewumi Victor
      • HBO Max Eliminates Approximately 200 'Sesame Street' Episodes
        HBO Max Eliminates Approximately 200 ‘Sesame Street’ Episodes
        Aug 19 Peter Olaoluwapo
      • Blue Water Assumes Administration of Rising River RV Resort and River House
        Blue Water Assumes Administration of Rising River RV Resort and River House
        Aug 19 Peter Olaoluwapo
      • FDA Approves Bayer’s Nubeqa for Wider Use in Prostate Cancer Subtype.
        FDA Approves Bayer’s Nubeqa for Wider Use in Prostate Cancer Subtype.
        Aug 9 Peter Olaoluwapo
      Subscribe & Get The LATEST Stock Pick Alerts
      I want e-mail alerts, updates, and offers and agree to the MicroSmallCap privacy policy.
      Advertise With Us
      • Write for Us
      • Submit Press Release
      • Submit Sponsored Post
      Company
      • Authors
      • Contact Us
      Legal
      • Terms of Use
      • Privacy Policy
      • DMCA Policy
      • Disclaimer
      Follow Us

      Copyright © 2026 | #170 - 422 Richards Street Vancouver, BC, Canada V6B 2Z4 | 1.800.340.9767

      Copyright © 2026 | Terms of Use | Privacy Policy | DMCA | Disclaimer | Authors

      #170 - 422 Richards Street Vancouver, BC, Canada V6B 2Z4 | 1.800.340.9767

      Subscribe & Get FREE MEI Pharma Email Alerts
      Get FREE MEI Pharma Email Alerts
      I want e-mail alerts, updates, and offers and agree to the MicroSmallCap privacy policy.
      x